Crispr Gene Editing In Humans
CRISPR gene editing in humans refers to the use of CRISPR associated protein (Cas) guided by a synthetic RNA to introduce targeted double strand breaks in human DNA, which are then repaired by the cell's own machinery to either disrupt, correct, or insert a genetic sequence. This guide is for life scientists, clinical researchers, and bioinformaticians who need a practical, evidence based framework for understanding, designing, and evaluating CRISPR applications in human cells.
The technology was adapted from a bacterial immune system and has rapidly become a standard tool in molecular biology and gene therapy development. As detailed in the NCBI Bookshelf resource on genome editing, the core mechanism involves a Cas9 nuclease, a single guide RNA that recognizes a 20 nucleotide target, and a short protospacer adjacent motif (PAM) sequence directly downstream of the target. After the double strand break, the cell deploys either non homologous end joining (NHEJ), which often creates small insertions or deletions (indels) that disrupt gene function, or homology directed repair (HDR), which can incorporate a provided donor template for precise edits.
Who should use this guide? Researchers planning in vitro experiments, translational scientists evaluating potential therapies, and students seeking a structured overview of practical considerations. The information is bounded by peer reviewed sources and open training materials, not speculative claims.
At a Glance
| Aspect | Key Information |
|---|---|
| Core tools | CRISPR Cas9, Cas12a, base editors, prime editors, CRISPRi/a |
| Main DNA repair pathways | NHEJ (gene knockout) and HDR (precise knock in or correction) |
| Delivery methods for human cells | Viral vectors (lentivirus, AAV), lipid nanoparticles, electroporation, ribonucleoprotein complexes |
| Primary applications | Disease modeling, functional genomics screens, gene therapy for monogenic disorders, cancer immunotherapy |
| Major risks | Off target edits, mosaicism in embryos, immune response to Cas proteins, unintended large deletions or rearrangements |
| Regulatory context | Clinical trials require FDA or equivalent oversight, ethical guidelines vary by jurisdiction |
Core Concepts and Mechanism
A CRISPR system consists of two essential components: a Cas nuclease and a guide RNA that directs the nuclease to a specific genomic locus. For the widely used Streptococcus pyogenes Cas9, the guide RNA includes a 20 nucleotide spacer sequence complementary to the target DNA, followed by a structural scaffold that binds Cas9. The nuclease then cleaves both DNA strands three base pairs upstream of the NGG PAM sequence.
Following the break, the cell's repair machinery determines the editing outcome. NHEJ is active throughout the cell cycle and frequently yields random indels that can shift the reading frame or create premature stop codons. In contrast, HDR is largely restricted to S and G2 phases and requires a homologous donor template, typically delivered as a single stranded oligonucleotide or a plasmid. The EMBL EBI Training module on genome editing provides interactive tutorials on how to choose between these repair strategies based on experimental goals.
Decision Points for Human Application
When designing a CRISPR experiment in human cells, several critical choices must be made.
Ex vivo versus in vivo editing. Ex vivo approaches involve removing cells from the patient, editing them in the laboratory, and returning them. This is common for immune cells (e.g., CAR T cells) and hematopoietic stem cells. In vivo editing requires directly delivering CRISPR components to the target tissue, which imposes stricter safety and delivery constraints.
Choice of nuclease. Cas9 is the most characterized, but Cas12a (Cpf1) recognizes a T rich PAM and leaves sticky ends, potentially improving HDR efficiency. Base editors and prime editors avoid double strand breaks altogether, reducing indel byproducts. The Galaxy Training Network offers workflows for designing guides for different nuclease systems.
Delivery vehicle. Viral vectors like adeno associated virus (AAV) are efficient but have limited cargo capacity (about 4.5 kb), making them unsuitable for large Cas proteins fused to additional domains. Lipid nanoparticles can deliver mRNA and guide RNA but have lower efficiency in some cell types. Ribonucleoprotein (RNP) complexes (purified Cas9 protein assembled with guide RNA) minimize off target effects because they are transient.
Target selection and off target prediction. Guide RNAs must be designed to minimize cleavage at similar sequences elsewhere in the genome. Many computational tools exist, and the Bioconductor package crisprScore provides empirical scoring functions to rank guides by predicted on target activity and off target risk.
Practical Workflow or Implementation Sequence
A robust CRISPR editing workflow in human cells typically follows these steps.
Step 1: Identify target genomic region and design guide RNAs. For gene knockout, choose guides targeting early constitutive exons. For precise editing, place the cut site within 10 bases of the intended edit. Use tools such as CRISPick or CHOPCHOP to generate candidate guides with high specificity scores. Validate that the target sequence is unique in the reference genome using BLAST.
Step 2: Assemble the CRISPR components. Order the guide RNA as two separate oligonucleotides for cloning into a plasmid (e.g., lentiCRISPRv2), or purchase synthetic crRNA and tracrRNA for RNP delivery. Confirm correct assembly by Sanger sequencing of the expression cassette.
Step 3: Introduce components into human cells. For adherent cell lines, transfection with lipofectamine or nucleofection is common. For primary cells or hard to transfect lines, consider lentiviral transduction at a low multiplicity of infection to minimize multiple integration events. Document cell type, passage number, and confluency at the time of delivery.
Step 4: Culture and select edited cells. If the vector contains a selection marker (e.g., puromycin resistance), apply antibiotic for 3 to 5 days. For HDR, consider enriching cells using a reporter system or fluorescence activated cell sorting.
Step 5: Validate editing efficiency. Extract genomic DNA 48 to 72 hours post transfection. PCR amplify the target region and perform Sanger sequencing followed by decomposition analysis (e.g., TIDE or ICE) to quantify indel frequency. For HDR, use droplet digital PCR or next generation sequencing. Raw sequencing data can be deposited in the NCBI Sequence Read Archive for public access.
Step 6: Assess off target effects. Use computational prediction to select the top candidate off target sites. Perform targeted deep sequencing of these loci. Whole genome sequencing is more comprehensive but costly.
Step 7: Clone and expand edited cells. For isogenic lines, dilute cells to single cells per well, expand, and screen by PCR and sequencing to identify homozygous or biallelic edits. Confirm expression changes at the RNA and protein levels.
Quality Checks
A well designed CRISPR experiment incorporates multiple quality controls. Always include a nontargeting guide RNA as a negative control to distinguish on target effects from transfection toxicity. Measure cell viability using a metabolic assay or live cell counting. For HDR experiments, include a donor only control to detect random integration.
Assay specificity by sequencing at least three independent biological replicates. Verify that the observed edit is not a polymorphism present in the parental cell line by sequencing the unedited line. Follow the recommendations in Bioconductor documentation for statistical analysis of CRISPR screen data to avoid false positives due to high variability.
Common Mistakes
Overlooking PAM requirements. A guide RNA cannot function if the target site lacks the correct PAM sequence. Always verify that the genome sequence contains NGG for SpCas9. Some researchers mistakenly design guides for regions without a PAM and then report failure.
Using a single guide RNA. One guide may not produce efficient cutting in a given cell type or locus. Design and test at least three guides per target. A study on XRCC5 and XRCC6 knockdown Knockdown of XRCC5 and XRCC6 activity using CRISPR/Cas9 technology enhances homology directed DNA repair at the CHST6 locus in HEK293 cells showed that targeting DNA repair factors can increase HDR efficiency, but this also depends on guide performance.
Ignoring cell cycle phase for HDR. Since HDR is largely confined to S/G2, synchronizing cells or using chemical enhancers (e.g., nocodazole, Scr7) can improve knock in rates. Unsynchronized populations often yield < 5% HDR.
Assuming all edits are clean. CRISPR can cause large deletions, chromosomal rearrangements, or complex insertions that are not detected by short read sequencing. Using long read sequencing or PCR spanning the entire editing window can reveal these errors.
Limits and Uncertainty
CRISPR editing in humans is not yet a universal cure for genetic diseases. Delivery to post mitotic tissues remains challenging, for example, editing in the brain requires crossing the blood brain barrier. Immunogenicity is a concern. Many humans have pre existing antibodies to Cas9 from prior infections with Staphylococcus aureus or Streptococcus pyogenes. A review of CRISPR based therapies for Huntington's disease and Friedreich's ataxia CRISPR Cas9 based therapies for Huntington's disease and Friedreich's ataxia: mechanisms, advances, and future perspectives notes that successful in vivo editing in the central nervous system requires vectors that target specific neuronal subtypes without triggering an inflammatory response.
Editing efficiency can vary widely between cell types, even within the same experiment. Epigenetic context at the target site influences Cas9 accessibility. For example, closed heterochromatin may require different guide designs or the use of Cas9 variants with altered PAM preferences.
The long term effects of genome edits are largely unknown. Off target mutations or on target rearrangements may have consequences that only appear after many cell divisions. In somatic cell therapy, the edited cells may eventually be replaced by unedited cells, limiting durability. In germline editing, heritable changes raise profound ethical questions that are still under international debate.
Frequently Asked Questions
Is CRISPR gene editing approved for use in human patients? Yes, several clinical trials are underway, primarily for ex vivo editing of blood cells to treat sickle cell disease and beta thalassemia. In 2023, the first CRISPR based therapy exagamglogene autotemcel received regulatory approval for sickle cell disease in the UK and US. No in vivo germline editing trials have been approved in most countries.
What is the difference between CRISPR knockout and CRISPRi? CRISPR knockout uses Cas9 to cut DNA and create indels, permanently disrupting the gene. CRISPRi uses a catalytically dead Cas9 (dCas9) fused to a repressor domain (e.g., KRAB) to block transcription without altering the DNA sequence. The effects are reversible and less likely to trigger DNA damage responses. A study in lung cancer cells CRISPRi Mediated Epigenetic Suppression of TERT Reduces Cell Growth in Non Small Cell Lung Cancer Cells demonstrated that CRISPRi can effectively silence a gene's expression.
Can CRISPR be used to edit human embryos? Research editing of human embryos is permitted in some countries for basic biology (e.g., studying early development) but is strictly regulated. In 2018, a controversial announcement of CRISPR edited babies led to widespread condemnation and new international guidelines. Clinical germline editing remains prohibited in nearly all jurisdictions.
How do I detect off target edits? Computational tools predict off target sites by allowing mismatches and bulges. The candidate sites are then amplified by targeted PCR and sequenced. For a comprehensive assessment, whole genome sequencing of edited clones can be compared to unedited controls. Store raw sequencing data in NCBI Sequence Read Archive to enable independent verification.
References and Further Reading
- NCBI Bookshelf: Genome Editing provides foundational concepts and ethical discussions.
- EMBL EBI Training: Genome Editing offers guided tutorials for guide design and validation.
- Galaxy Training Network: CRISPR workflows includes hands on exercises for computational analysis.
- Bioconductor: crisprScore package for guide ranking and off target predictions.
- Knockdown of XRCC5 and XRCC6 activity using CRISPR/Cas9 technology enhances homology directed DNA repair at the CHST6 locus in HEK293 cells demonstrates how manipulating repair factors can improve HDR.
- C. elegans model for functional analysis of conserved ADPKD variants shows how CRISPR can be used in model organisms to study human disease variants.
- CRISPR Cas9 based therapies for Huntington's disease and Friedreich's ataxia reviews challenges for CNS editing.
- CRISPRi Mediated Epigenetic Suppression of TERT showcases an alternative to DNA cutting.
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools illustrates CRISPR applications in vaccine development.
- Engineering extracellular vesicle biogenesis for therapeutic gene delivery discusses cutting edge delivery strategies.